Zacks Investment Research upgraded shares of SPECTRANETICS (SPNC) from UNDERPERFORM to NEUTRAL on May 24, 2013, with a target price of $19.80.
Spectranetics Corp. is a medical device company engaged in the development, manufacturing, marketing and distribution of its technology for interventional cardiovascular therapy. The Company's CVX-300 excimer laser system is the only excimer laser system approved by the FDA for multiple cardiovascular procedures. The technology has been designed for use in multiple cardiovascular applications, including coronary angioplasty and the removal of pacemaker and ICD leads. (press release)
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on SPECTRANETICS (SPNC),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment